WO2012176865A1 - ヒアルロン酸またはその塩およびプロピレングリコールを含有する点眼液 - Google Patents
ヒアルロン酸またはその塩およびプロピレングリコールを含有する点眼液 Download PDFInfo
- Publication number
- WO2012176865A1 WO2012176865A1 PCT/JP2012/065957 JP2012065957W WO2012176865A1 WO 2012176865 A1 WO2012176865 A1 WO 2012176865A1 JP 2012065957 W JP2012065957 W JP 2012065957W WO 2012176865 A1 WO2012176865 A1 WO 2012176865A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ophthalmic solution
- concentration
- propylene glycol
- amount
- hyaluronic acid
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
Definitions
- the present invention relates to an aqueous ophthalmic solution containing hyaluronic acid or a salt thereof in a concentration of 0.03-0.5% (w / v) and propylene glycol in a concentration of 0.1-1.0% (w / v).
- the ophthalmic solution contains benzalkonium chloride at a concentration of 0.001 to 0.002% (w / v) as the only preservative, and the osmotic pressure ratio of the ophthalmic solution is 0.9 to
- the present invention relates to an aqueous ophthalmic solution containing an ionic tonicity agent having a concentration of 1.1.
- the present invention also improves the preservative efficacy of eye drops containing sodium hyaluronate at a concentration of 0.1 or 0.3% (w / v) and benzalkonium chloride as the only preservative, A method for setting the kinematic viscosity of an ophthalmic solution to 3.0 to 4.0 or 17 to 30 mm 2 / s, and preventing dripping of the ophthalmic solution, wherein the concentration in the ophthalmic solution is 0.1 or 0.1.
- Dry eye is a disease that begins with symptoms of discomfort such as dry eyes and bloating, and when it gets worse, it causes great problems in daily life.
- the number of dry eye patients is increasing year by year with the arrival of an aging society and the increase of VDT (video display terminal) work for personal computers, etc.
- the estimated number of patients in the United States is more than 10 million, and 800 in Japan. It is said that there are more than 10,000 people.
- eye drops are the most common dry eye treatment.
- eye drops containing sodium hyaluronate are widely used for dry eye treatment.
- the ophthalmic solution containing sodium hyaluronate (hereinafter also simply referred to as “sodium hyaluronate ophthalmic solution”) is intended to be used multiple times and can be opened and resealed freely.
- Dosage type (Hirayan (registered trademark) ophthalmic solution 0.1%, Hirayan (registered trademark) ophthalmic solution 0.3%, etc.), and unit dose type (Hirayane (registered trademark) mini ophthalmic solution for single use ) 0.1%, such as Hyalein (registered trademark) mini ophthalmic solution 0.3%) is present.
- benzalkonium chloride is added as a preservative because the cap is opened and resealed, while the unit dose type is a single use (use up) As such, no preservatives are added.
- preservatives such as benzalkonium chloride have a risk of inducing corneal damage.
- corneal epithelial damage may be caused in a concentration-dependent manner.
- unit dose type sodium hyaluronate ophthalmic solution is used for severe dry eye patients.
- JP 2004-359629 A Patent Document 1
- JP 2009-196903 A Patent Document 2
- JP 2009-161454 A Patent Document 3
- sodium hyaluronate benzalkonium.
- eye drops containing chloride and propylene glycol have been disclosed, the benzalkonium chloride concentration in the eye drops is 0.0025% or less, and has sufficient storage efficacy and is a conventional hyaluron What has the same physicochemical properties as sodium acid ophthalmic solution is not described at all.
- the inventors of the present invention cannot obtain sufficient storage efficacy with sodium hyaluronate ophthalmic solution to which 0.002% (w / v) benzalkonium chloride is added, whereas when propylene glycol is added, It has been found that sufficient preservation efficacy can be obtained even when the ruconium chloride concentration is reduced to 0.001% (w / v).
- the present inventors have also found that the propylene glycol-containing sodium hyaluronate ophthalmic solution is difficult to drip and has the effect of protecting the corneal epithelial cells from drying, as will be described later.
- the present invention provides an aqueous solution containing hyaluronic acid or a salt thereof at a concentration of 0.03-0.5% (w / v) and propylene glycol at a concentration of 0.1-1.0% (w / v).
- Ophthalmic solution which contains benzalkonium chloride at a concentration of 0.001 to 0.002% (w / v) as the only preservative, and has an osmotic pressure ratio of 0.
- An ophthalmic solution containing an ionic tonicity agent having a concentration of 9 to 1.1 hereinafter also simply referred to as “the present ophthalmic solution”).
- Another aspect of the present invention is the present ophthalmic solution containing a buffer and a pH adjuster in an amount to adjust the pH to 6.0 to 7.0.
- Another aspect of the present invention is the present ophthalmic solution containing edetate at a concentration of 0.001 to 0.1% (w / v).
- Another aspect of the present invention is the present ophthalmic solution in which the concentration of hyaluronic acid or a salt thereof is 0.1 to 0.3% (w / v).
- Another aspect of the present invention is the ophthalmic solution having a propylene glycol concentration of 0.25 to 0.75% (w / v).
- Another aspect of the present invention is the present ophthalmic solution having a benzalkonium chloride concentration of 0.001 to 0.0015% (w / v).
- the present invention also improves the storage efficacy of aqueous eye drops containing sodium hyaluronate at a concentration of 0.1 or 0.3% (w / v) and benzalkonium chloride as the only preservative,
- benzalkonium chloride in an amount of 0.001 to 0.002% (w / v) in the ophthalmic solution
- Propylene glycol in an amount of 0.1 to 1.0% (w / v) and an ionic tonicity agent in an amount of osmotic pressure ratio of the ophthalmic solution of 0.9 to 1.1 are mixed.
- Step (a), adjusting the pH of the ophthalmic solution to 6.0-7.0 b), and comprising the step (c) of the ophthalmic solution is filled into eye drop container (hereinafter simply collectively referred to also referred to as "the present method") is also.
- step (a) of the present method it is preferable to further mix edetate in an amount such that the concentration in the ophthalmic solution is 0.001 to 0.1% (w / v).
- step (a) of the present method it is preferable to mix propylene glycol in such an amount that the concentration in the ophthalmic solution is 0.25 to 0.75% (w / v).
- step (a) of the present method it is preferable to mix benzalkonium chloride in an amount such that the concentration in the ophthalmic solution is 0.001 to 0.0015% (w / v).
- this ophthalmic solution has a benzalkonium chloride concentration in the ophthalmic solution of 0.002% (w / v) or less, it exhibits sufficient storage efficacy by containing propylene glycol, It has an acceptable kinematic viscosity and osmotic pressure ratio as an ophthalmic solution containing hyaluronic acid or a salt thereof (hereinafter also simply referred to as “hyaluronic acid ophthalmic solution”). Further, as is apparent from the results of the liquid dripping confirmation test and the corneal epithelial cell protective action confirmation test described later, this ophthalmic solution is difficult to dripping and also has the effect of protecting the corneal epithelial cells from drying.
- This ophthalmic solution is an aqueous ophthalmic solution containing hyaluronic acid or a salt thereof at a concentration of 0.03-0.5% (w / v) and propylene glycol at a concentration of 0.1-1.0% (w / v).
- the ophthalmic solution contains benzalkonium chloride at a concentration of 0.001 to 0.002% (w / v) as the only preservative, and the osmotic pressure ratio of the ophthalmic solution is 0.9. It is characterized by containing an ionic tonicity agent at a concentration of -1.1.
- aqueous eye drop means an eye drop based on water.
- This ophthalmic solution is used not only for keratoconjunctival epithelial disorders associated with intrinsic diseases such as dry eye (dry eye syndrome), Sjogren's syndrome, and Stevens-Johnson syndrome, but also for external causes caused by postoperative, drug-related, trauma, contact lens wear It can also be used to treat keratoconjunctival epithelial disorders associated with sexually transmitted diseases.
- Such an ophthalmic solution has a sufficient preservative effect by containing propylene glycol even though the benzalkonium chloride concentration in the ophthalmic solution is 0.002% (w / v) or less.
- this ophthalmic solution is difficult to drip and has the effect of protecting the corneal epithelial cells from drying.
- the hyaluronic acid in the present invention is a compound represented by the following general formula (1).
- hyaluronic acid Preferred as the “hyaluronic acid” in the present invention is hyaluronic acid having an average molecular weight of 500,000 to 3.9 million, and more preferred is hyaluronic acid having an average molecular weight of 500,000 to 1,200,000.
- the salt of hyaluronic acid is not particularly limited as long as it is a pharmaceutically acceptable salt.
- Salts with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, sulfuric acid, phosphoric acid, acetic acid, fumaric acid Acid, maleic acid, succinic acid, citric acid, tartaric acid, adipic acid, gluconic acid, glucoheptic acid, glucuronic acid, terephthalic acid, methanesulfonic acid, lactic acid, hippuric acid, 1,2-ethanedisulfonic acid, isethionic acid, lactobionic acid Organic acids such as oleic acid, pamoic acid, polygalacturonic acid, stearic acid, tannic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, lauryl sulfate, methyl s
- the “hyaluronic acid salt” in the present invention is preferably a sodium salt represented by the following general formula (2) (hereinafter also referred to as “sodium hyaluronate”).
- hyaluronic acid or a salt thereof may take the form of a hydrate or a solvate.
- crystal polymorphs and crystal polymorph groups (crystal polymorph systems) exist in hyaluronic acid or a salt, hydrate or solvate thereof
- crystal polymorphs and crystal polymorph groups (crystal polymorphs) System) is also included within the scope of the present invention.
- the crystal polymorphism group means that the crystal form changes depending on the conditions and state of production, crystallization and storage of these crystals (including the formulated state in this state). Means the individual crystal forms at each stage and the whole process.
- Hyaluronic acid or a salt thereof can be produced according to a usual method in the field of synthetic organic chemistry, or can be produced according to the method described in JP-A-1-115902.
- the “hyaluronic acid or a salt thereof” of the present invention may be one commercially available from Sigma, for example, “sodium hyaluronate” is commercially available from Sigma (catalog number: H5388). .
- the ophthalmic solution may contain an active ingredient other than “hyaluronic acid or a salt thereof”, but preferably contains “hyaluronic acid or a salt thereof” as the only active ingredient.
- the concentration of “hyaluronic acid or a salt thereof” in this ophthalmic solution is 0.03-0.5% (w / v), preferably 0.1-0.3% (w / v), More preferably, it is 0.1% (w / v) or 0.3% (w / v).
- concentration of hyaluronic acid or a salt thereof means both the concentrations of “hyaluronic acid (free form)” and “salt of hyaluronic acid”.
- concentration of “hyaluronic acid (free body)” in the ophthalmic solution is 0.1% (w / v) It means both when the concentration of “hyaluronic acid salt” is 0.1% (w / v).
- the concentration of “propylene glycol” in the ophthalmic solution is 0.1 to 1.0% (w / v), preferably 0.25 to 0.75% (w / v).
- Benzalkonium chloride is a compound represented by the following general formula (3).
- R represents an alkyl group having 8 to 18 carbon atoms.
- the “benzalkonium chloride” of the present invention is preferably one in which R represents “C 12 H 25 ” in the general formula (3) (hereinafter also referred to as “benzalkonium chloride (C12)”). is there.
- the concentration of “benzalkonium chloride” in the ophthalmic solution is 0.001 to 0.002% (w / v), preferably 0.001 to 0.0015% (w / v).
- containing benzalkonium chloride as the only preservative means that the ophthalmic solution contains benzalkonium chloride, while benzethonium chloride, chlorhexidine gluconate, parabens, sorbine It means not containing any of acids and salts thereof, chlorobutanol, boric acid, borax and chlorite.
- “contains an ionic tonicity agent at a concentration of 0.9 to 1.1 for the osmotic pressure ratio of the ophthalmic solution” means that, in addition to propylene glycol, etc. It means that the osmotic pressure ratio of the ophthalmic solution is adjusted to the range of “0.9 to 1.1” by further adding a tonicity agent.
- the osmotic pressure ratio of the present ophthalmic solution can be easily measured using an automatic osmotic pressure analyzer.
- the ionic tonicity agent used in the present invention means ionic tonicity agents such as sodium chloride, potassium chloride, calcium chloride, magnesium chloride.
- the ophthalmic solution preferably contains an amount of a buffer and a pH adjuster that adjust the pH of the ophthalmic solution to 6.0 to 7.0.
- “contains a buffer and a pH adjuster in such an amount that the pH of the ophthalmic solution is 6.0 to 7.0” means that by adding the buffer and the pH adjuster to the ophthalmic solution, This means that the pH of the ophthalmic solution is adjusted to the range of “6.0 to 7.0”, and if the pH of the ophthalmic solution can be adjusted to the range, the buffering agent and the pH adjusting agent
- the addition amount (concentration) is not particularly limited.
- the “buffering agent” in the present invention include sodium phosphate, sodium hydrogen phosphate, sodium dihydrogen phosphate, sodium acetate, epsilon-aminocaproic acid, etc., but epsilon-aminocaproic acid is particularly preferable. .
- boric acid and borax are not included in the “buffering agent” in the present invention.
- the “pH adjusting agent” in the present invention is not particularly limited as long as it can adjust the pH of the ophthalmic solution, and specific examples include dilute hydrochloric acid and sodium hydroxide.
- This ophthalmic solution has a kinematic viscosity comparable to that of conventional sodium hyaluronate ophthalmic solutions.
- concentration of hyaluronic acid or a salt thereof of the present ophthalmic solution is 0.1% (w / v)
- the kinematic viscosity, Hyalein ® ophthalmic solution 0.1% or Hyalein (TM) Mini Ophthalmic solution 0.1% It is within the range of “3.0 to 4.0 mm 2 / s” described in the pharmaceutical interview form.
- the concentration of hyaluronic acid or a salt thereof in the ophthalmic solution is 0.3% (w / v)
- the kinematic viscosity is 0.3% of Hyalein (registered trademark) ophthalmic solution or Hyalein (registered trademark) Mini.
- Ophthalmic solution 0.3% It is within the range of “17-30 mm 2 / s” described in the pharmaceutical interview form.
- the ophthalmic solution preferably contains edetate in a concentration of 0.001 to 0.1% (w / v).
- the “edetate” in the present invention is a salt of edetic acid (ethylenediaminetetraacetic acid) such as monosodium edetate, disodium edetate, trisodium edetate, tetrasodium edetate, and hydrates thereof.
- Means. Preferred as the “edetate” of the present invention is disodium edetate dihydrate (hereinafter also referred to as “sodium edetate hydrate”).
- a pharmaceutically acceptable additive can be added to the ophthalmic solution as needed, but the ophthalmic solution is preferably an additive that is not specified to be contained, It does not contain anything that affects the effect of the present ophthalmic solution, and more preferably does not contain additives that are not explicitly stated to be contained.
- the present invention provides a preferred embodiment of the ophthalmic solution described above, hyaluronic acid or a salt thereof at a concentration of 0.03-0.5% (w / v), 0.1-1.0% (w / v) Propylene glycol at a concentration, benzalkonium chloride at a concentration of 0.001 to 0.002% (w / v), and an ionic tonicity agent at a concentration such that the osmotic pressure ratio of the ophthalmic solution is 0.9 to 1.1
- An aqueous solution consisting essentially of a buffer and pH adjuster in an amount to bring the pH of the ophthalmic solution to 6.0-7.0, and edetate in a concentration of 0.001-0.1% (w / v) Provide eye drops.
- the concentration of hyaluronic acid or a salt thereof is 0.1 to 0.3% (w / v), and the concentration of propylene glycol is 0.25 to 0.75% (w / v).
- the concentration of benzalkonium chloride is preferably 0.001 to 0.0015% (w / v).
- “improving storage efficacy” means increasing the amount of preservative added for sodium hyaluronate ophthalmic solution containing benzalkonium chloride at a concentration of 0.002% (w / v) or less. This means that the ophthalmic solution is allowed to pass a prescribed preservation efficacy test (for example, the preservation efficacy test of the 15th revision Japanese Pharmacopoeia).
- “to prevent dripping” means that when an eye drop operation is performed after filling a sodium hyaluronate eye drop into an eye drop container, compared to sodium hyaluronate eye drop that does not contain propylene glycol, This means that the frequency of occurrence of a phenomenon (liquid dripping) in which the ophthalmic solution is drawn from the tip of the ophthalmic container to the outside is reduced.
- ingredients other than sodium hyaluronate, benzalkonium chloride, propylene glycol and ionic tonicity agent can be mixed, and in particular, the concentration in sodium hyaluronate ophthalmic solution
- edetate is mixed in an amount of 0.001 to 0.1% (w / v).
- Step (b) of the present method means adding a buffer and a pH adjuster to the sodium hyaluronate ophthalmic solution to adjust the pH to a range of “6.0 to 7.0”.
- the addition amount (concentration) of the buffer and the pH adjuster is not particularly limited.
- the ophthalmic container filled with sodium hyaluronate ophthalmic solution is not particularly limited as long as it is normally used as an ophthalmic container, but a polyethylene eye drop container is particularly preferable.
- steps other than steps (a), (b) and (c) can be included.
- Example preparation ⁇ Comparison prescription 1, 2> Sodium hyaluronate 0.3g, sodium chloride 0.7g, potassium chloride 0.15g, epsilon-aminocaproic acid 0.2g, sodium edetate hydrate 0.01g and benzalkonium chloride (C12) 0.0025g in water Dissolved in 100 to 100 mL, and diluted with hydrochloric acid and / or sodium hydroxide to pH 6.0 was set as Comparative Formula 1 and pH 7.0 was set as Comparative Formula 2.
- ⁇ Prescription 2> It was prepared in the same manner as in Formula 1 except that the amount of sodium hyaluronate added was 0.1 g and the amount of benzalkonium chloride (C12) added was 0.0012 g.
- the preservation efficacy test was conducted in accordance with the preservation efficacy test method of the 15th revision Japanese Pharmacopoeia (hereinafter, also simply referred to as “Japanese Pharmacopoeia”).
- Escherichia Coli E. coli
- Pseudomonas aeruginosa P. aeruginosa
- Staphylococcus aureus S. aureus
- Candida albicans C. albicans
- Candida albicans C. albicans
- Candida albicans C. albicans
- Test results The test results are shown in Table 1. In Table 1, “ND” indicates that no bacteria were detected.
- Example preparation ⁇ Comparison prescription> Sodium hyaluronate 0.3 g, epsilon-aminocaproic acid 0.2 g, sodium chloride 0.8 g, benzalkonium chloride (C12) 0.0015 g and edetate sodium hydrate 0.01 g are dissolved in water to make 100 mL.
- a comparative formulation was prepared by adding dilute hydrochloric acid and / or sodium hydroxide to a pH of 6.5 and an osmotic pressure ratio of 1.0.
- ⁇ Prescription 1-5> It was prepared in the same manner as in the comparative formulation except that the osmotic pressure ratio was adjusted to 1.0 by appropriately changing the addition amounts of sodium chloride and propylene glycol (see Table 2).
- the osmotic pressure ratio and kinematic viscosity tolerance range of 0.3% (w / v) sodium hyaluronate ophthalmic solution are “0.9 to 1.1” and “17 to 30 mm 2 , respectively. / S ". Therefore, after adjusting the osmotic pressure ratio of sodium hyaluronate ophthalmic solution to “0.9 to 1.1” using propylene glycol and an ionic tonicity agent, the kinematic viscosity of the ophthalmic solution was measured. In the kinematic viscosity measurement test, the kinematic viscosity at a measurement temperature of 30 ° C.
- the blending concentration of propylene glycol is 1% (w / v) or less
- the kinematic viscosity of 0.1% (w / v) sodium hyaluronate ophthalmic solution is within an allowable range (3.0 to 4.0 mm 2 / s). From the above, it was shown that when propylene glycol is blended with hyaluronic acid ophthalmic solution, the blending concentration needs to be 1.0% (w / v) or less.
- a polyethylene eye drop container was filled with 5 mL of a propylene glycol-free formulation or propylene glycol-containing formulation, and the same operation as that performed by five healthy subjects during instillation was performed 6 times each. For each operation, it was evaluated whether or not a liquid sag (a phenomenon in which the ophthalmic solution was drawn from the tip of the ophthalmic container to the outside) occurred.
- a liquid sag a phenomenon in which the ophthalmic solution was drawn from the tip of the ophthalmic container to the outside
- SV40 immortalized human corneal epithelial cells (HCE-T: RIKEN, BioResource Center, Cell No .: RCB2280) were seeded in a 96-well plate (1 ⁇ 10 4 cells / well) and cultured for one day in SHEM medium .
- the medium was 0.25% (w / v) propylene glycol, 0.03% (w / v) sodium hyaluronate or 0.25% (w / v) propylene glycol and 0.03% (w / v)
- the corneal epithelial cells were cultured for 1 hour (hereinafter referred to as “propylene glycol alone group”, “hyaluronic acid alone group” or “propylene glycol / hyaluronic acid combination respectively”, respectively. Also referred to as a group).
- the group in which the corneal epithelial cells were cultured for 1 hour after changing to a test substance-free D-MEM / F12 medium was defined as a “base group”. After the culture, the medium of each group was replaced with a test substance-free D-MEM / F12 medium, and then a dry load was applied for 7.5 minutes. After loading, live cell activity (corresponding to absorbance at 490 nm) was measured using Cell Proliferation Assay Kit (Promega, catalog number: G3580).
- formulation example The pharmaceutical agent of the present invention will be described more specifically with formulation examples, but the present invention is not limited to these formulation examples.
- the hyaluronic acid ophthalmic solution of the present invention contains propylene glycol in spite of the benzalkonium chloride concentration in the ophthalmic solution being 0.002% (w / v) or less. On the other hand, it has an acceptable osmotic pressure ratio and kinematic viscosity as hyaluronic acid ophthalmic solution. Furthermore, since the hyaluronic acid ophthalmic solution of the present invention is difficult to dripping and has the effect of protecting corneal epithelial cells from drying, it is expected to be an ophthalmic solution that can treat dry eye more effectively.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本発明における「ヒアルロン酸」として好ましいのは、平均分子量が50万~390万のヒアルロン酸であり、さらに好ましいのは、平均分子量が50万~120万のヒアルロン酸である。
本発明における「ヒアルロン酸またはその塩」は、水和物または溶媒和物の形態をとっていてもよい。
本発明の「ベンザルコニウム塩化物」として好ましいのは、上記一般式(3)においてRが「C12H25」を示すもの(以下、「ベンザルコニウム塩化物(C12)」ともいう)である。
プロピレングリコールがヒアルロン酸点眼液の保存効力に与える影響を確認するため、保存効力試験を行った。
<比較処方1、2>
ヒアルロン酸ナトリウム0.3g、塩化ナトリウム0.7g、塩化カリウム0.15g、イプシロン-アミノカプロン酸0.2g、エデト酸ナトリウム水和物0.01gおよびベンザルコニウム塩化物(C12)0.0025gを水に溶解して100mLとし、希塩酸および/または水酸化ナトリウムを添加してpH6.0としたものを比較処方1、pH7.0としたものを比較処方2とした。
ベンザルコニウム塩化物(C12)の添加量を0.002gとした点を除いては上記比較処方1および2と同様にして調製された。
ヒアルロン酸ナトリウム0.3g、塩化ナトリウム0.7g、プロピレングリコール0.25g、イプシロン-アミノカプロン酸0.2g、エデト酸ナトリウム水和物0.01gおよびベンザルコニウム塩化物(C12)0.001gを水に溶解して100mLとし、希塩酸および/または水酸化ナトリウムを添加してpH6.0とした。
ヒアルロン酸ナトリウムの添加量を0.1g、ベンザルコニウム塩化物(C12)の添加量を0.0012gとした点を除いては上記処方1と同様にして調製された。
保存効力試験は、第十五改正日本薬局方(以下、単に「日本薬局方」ともいう)の保存効力試験法に準拠して行った。本試験では、試験菌として、Esherichia Coli(E.coli)、Pseudomonas aeruginosa(P.aeruginosa)、Staphylococcus aureus(S.aureus)、Candida albicans(C.albicans)およびAspergillus niger(A.niger)を用いた。
試験結果を表1に示す。表1中、「N.D.」は、菌が検出されなかったことを示す。
表1に示された通り、ヒアルロン酸ナトリウム点眼液は、0.0025%(w/v)ベンザルコニウム塩化物存在下では許容されるpHの範囲内(pH6.0および7.0)において、「日本薬局方 参考情報 保存効力試験 カテゴリーIA」の判定基準に適合したが、0.002%(w/v)ベンザルコニウム塩化物存在下ではpH6.0において同判定基準に不適合であり、十分な保存効力を有さないことが明らかとなった。次いで、0.25%(w/v)プロピレングリコール存在下で、保存効力がより弱くなるpH6.0における保存効力を評価したところ、0.1%(w/v)ヒアルロン酸ナトリウム点眼液では、ベンザルコニウム塩化物濃度0.0012%(w/v)で「日本薬局方 参考情報 保存効力試験 カテゴリーIA」の判定基準に適合し、また、0.3%(w/v)ヒアルロン酸ナトリウム点眼液では、ベンザルコニウム塩化物濃度0.001%(w/v)でも同基準に適合し、それぞれ十分な保存効力を有することが明らかとなった。以上から、ヒアルロン酸点眼液では、プロピレングリコールを添加することで、ベンザルコニウム塩化物濃度を0.002%(w/v)以下としても十分な保存効力を奏することが示された。
プロピレングリコールを配合したヒアルロン酸点眼液の浸透圧比を0.9~1.1に調整した場合の該点眼液の動粘度を確認するため、動粘度測定試験を行った。
<比較処方>
ヒアルロン酸ナトリウム0.3g、イプシロン-アミノカプロン酸0.2g、塩化ナトリウム0.8g、ベンザルコニウム塩化物(C12)0.0015gおよびエデト酸ナトリウム水和物0.01gを水に溶解して100mLとし、希塩酸および/または水酸化ナトリウムを添加してpH6.5、浸透圧比1.0としたものを比較処方とした。
塩化ナトリウムとプロピレングリコールの添加量を適宜変化させて浸透圧比を1.0に調整した点(表2参照)を除いては、上記比較処方と同様にして調製された。
ヒアレインインタビューフォームの4頁には、0.3%(w/v)ヒアルロン酸ナトリウム点眼液の浸透圧比および動粘度の許容幅が、それぞれ「0.9~1.1」および「17~30mm2/s」であることが記載されている。そこで、プロピレングリコールおよびイオン性等張化剤を用いてヒアルロン酸ナトリウム点眼液の浸透圧比を「0.9~1.1」に調整した後、該点眼液の動粘度を測定した。なお、動粘度測定試験は、「日本薬局方 一般試験法 粘度測定法 第1法 毛細管粘度計法」に従い、測定温度30℃における動粘度を測定した。また、浸透圧比は、「日本薬局方 一般試験法 浸透圧測定法」に従い、自動浸透圧分析装置(アークレイ社製)を用いて測定した。
結果を表2に示す。
表2から明らかなように、プロピレングリコールの配合濃度が1%(w/v)以下では、0.3%(w/v)ヒアルロン酸ナトリウム点眼液の動粘度が許容範囲内(17~30mm2/s)となった一方、それ以上の濃度では動粘度の許容範囲を超えることが示された。また、上記結果より、プロピレングリコールの配合濃度が1%(w/v)以下であれば、0.1%(w/v)ヒアルロン酸ナトリウム点眼液の動粘度も許容範囲内(3.0~4.0mm2/s)となるものと推測される。以上より、ヒアルロン酸点眼液にプロピレングリコールを配合する場合、その配合濃度を1.0%(w/v)以下とする必要性があることが示された。
プロピレングリコールがヒアルロン酸点眼液の液ダレに及ぼす影響を確認するため、液ダレ確認試験を行った。
・プロピレングリコール非含有処方
市販の「ヒアレイン(登録商標)点眼液0.1%」を使用した。
ヒアルロン酸ナトリウム(0.1g)、緩衝剤(イプシロン-アミノカプロン酸)、塩化ナトリウム、プロピレングリコール、ベンザルコニウム塩化物(C12)およびエデト酸ナトリウム水和物を水に溶解して100mL(浸透圧比:0.9~1.1)とし、希塩酸および/または水酸化ナトリウムを添加してpH6.5とした。
ポリエチレン製点眼容器にプロピレングリコール非含有処方またはプロピレングリコール含有処方5mLを充填し、健常人5名が点眼時に行うのと同じ操作を6回ずつ実施した。操作毎に、液ダレ(点眼液が点眼容器の先端から外部につたってしまう現象)が生じたか否かを評価した。
結果を表3に示す。
表3から明らかなように、プロピレングリコール非含有処方では液ダレする場合があったのに対し、プロピレングリコール含有処方では液ダレは全く認められなかった。以上から、本点眼液では従来のプロピレングリコールが配合されていないヒアルロン酸点眼液に比べ、液ダレ性が改善していることが示された。
プロピレングリコール含有ヒアルロン酸点眼液が乾燥負荷による角膜上皮細胞障害に及ぼす影響を検討するため、角膜上皮細胞保護作用確認試験を行った。
SV40不死化ヒト角膜上皮細胞:(HCE-T:理化学研究所、バイオリソースセンター、Cell No.:RCB2280)を96ウエルプレートに播種(1×104細胞/ウエル)し、SHEM培地で1日培養した。翌日、培地を0.25%(w/v)プロピレングリコール、0.03%(w/v)ヒアルロン酸ナトリウムまたは0.25%(w/v)プロピレングリコールおよび0.03%(w/v)ヒアルロン酸ナトリウム含有D-MEM/F12培地に交換した後、前記角膜上皮細胞を1時間培養した(以下、それぞれ、「プロピレングリコール単独群」、「ヒアルロン酸単独群」または「プロピレングリコール/ヒアルロン酸併用群」ともいう)。なお、被験物質不含有D-MEM/F12培地に交換した後、前記角膜上皮細胞を1時間培養した群を「基剤群」とした。培養後、各群の培地を被験物質不含有D-MEM/F12培地に交換してから、乾燥負荷を7.5分間行った。負荷後、Cell Proliferation Assay Kit)(Promega社製、カタログ番号:G3580)を用いて、生細胞活性(490nmの吸光度に相当する)を測定した。
試験結果を図1に示す。
図1から明らかなように、乾燥負荷による角膜上皮細胞の生細胞活性の低下(基剤群参照)は、プロピレングリコールまたはヒアルロン酸の単独処置では十分には抑制されなかった(プロピレングリコール単独群、ヒアルロン酸単独群参照)。一方で、プロピレングリコール/ヒアルロン酸ナトリウム併用群においては、驚くべきことに該生細胞活性の低下が有意に抑制されることが確認された。以上の結果より、プロピレングリコール含有ヒアルロン酸点眼液は、角膜上皮細胞を乾燥から保護する作用を有するものと考えられる。
製剤例を挙げて本発明の薬剤をさらに具体的に説明するが、本発明はこれらの製剤例にのみ限定されるものではない。
点眼剤(0.1%(w/v)) 100ml中
ヒアルロン酸ナトリウム 0.1g
イプシロンアミノカプロン酸 0.2g
塩化ナトリウム 0.6g
プロピレングリコール 0.5g
ベンザルコニウム塩化物(C12) 0.001~0.002g
エデト酸ナトリウム水和物 0.001~0.1g
希塩酸 適量
水酸化ナトリウム 適量
滅菌精製水 適量
滅菌精製水にヒアルロン酸ナトリウムおよびそれ以外の上記成分を加え、これらを十分に混合することで、pH6.0~7.0、浸透圧比0.9~1.1である0.1%(w/v)ヒアルロン酸ナトリウム点眼液を調製できる。
点眼剤(0.3%(w/v)) 100ml中
ヒアルロン酸ナトリウム 0.3g
イプシロンアミノカプロン酸 0.2g
塩化ナトリウム 0.5g
プロピレングリコール 0.75g
ベンザルコニウム塩化物(C12) 0.001~0.002g
エデト酸ナトリウム水和物 0.001~0.1g
希塩酸 適量
水酸化ナトリウム 適量
滅菌精製水 適量
滅菌精製水にヒアルロン酸ナトリウムおよびそれ以外の上記成分を加え、これらを十分に混合することで、pH6.0~7.0、浸透圧比0.9~1.1である0.3%(w/v)ヒアルロン酸ナトリウム点眼液を調製できる。
Claims (13)
- 0.03~0.5%(w/v)の濃度のヒアルロン酸またはその塩および0.1~1.0%(w/v)の濃度のプロピレングリコールを含有する水性点眼液であって、該点眼液が0.001~0.002%(w/v)の濃度のベンザルコニウム塩化物を唯一の防腐剤として含有し、且つ該点眼液の浸透圧比を0.9~1.1とする濃度のイオン性等張化剤を含有する、点眼液。
- 該点眼液のpHを6.0~7.0とする量の緩衝剤およびpH調節剤を含有する、請求項1に記載の点眼液。
- 0.001~0.1%(w/v)の濃度のエデト酸塩を含有する、請求項1または2に記載の点眼液。
- ヒアルロン酸またはその塩の濃度が0.1~0.3%(w/v)である、請求項1に記載の点眼液。
- プロピレングリコールの濃度が0.25~0.75%(w/v)である、請求項1に記載の点眼液。
- ベンザルコニウム塩化物の濃度が0.001~0.0015%(w/v)である、請求項1に記載の点眼液。
- 0.03~0.5%(w/v)の濃度のヒアルロン酸またはその塩、0.1~1.0%(w/v)の濃度のプロピレングリコール、0.001~0.002%(w/v)の濃度のベンザルコニウム塩化物、点眼液の浸透圧比を0.9~1.1とする濃度のイオン性等張化剤、点眼液のpHを6.0~7.0とする量の緩衝剤およびpH調節剤、並びに0.001~0.1%(w/v)の濃度のエデト酸塩から実質的になる水性点眼液。
- ヒアルロン酸またはその塩の濃度が0.1~0.3%(w/v)であり、プロピレングリコールの濃度が0.25~0.75%(w/v)であり、ベンザルコニウム塩化物の濃度が0.001~0.0015%(w/v)である、請求項7に記載の点眼液。
- 0.1%(w/v)の濃度のヒアルロン酸ナトリウムおよび唯一の防腐剤としてベンザルコニウム塩化物を含有する水性点眼液の保存効力を向上させると共に、該点眼液の動粘度を3.0~4.0mm2/sとし、且つ該点眼液の液ダレを防止する方法であって、
該点眼液中の濃度が0.1%(w/v)となる量のヒアルロン酸ナトリウム、該点眼液中の濃度が0.001~0.002%(w/v)となる量のベンザルコニウム塩化物、該点眼液中の濃度が0.1~1.0%(w/v)となる量のプロピレングリコール、および該点眼液の浸透圧比が0.9~1.1となる量のイオン性等張化剤を混合するステップ(a);
該点眼液のpHを6.0~7.0に調整するステップ(b);および
該点眼液を点眼容器に充填するステップ(c)を含む、方法。 - 0.3%(w/v)の濃度のヒアルロン酸ナトリウムおよび唯一の防腐剤としてベンザルコニウム塩化物を含有する水性点眼液の保存効力を向上させると共に、該点眼液の動粘度を17~30mm2/sとし、且つ該点眼液の液ダレを防止する方法であって、
該点眼液中の濃度が0.3%(w/v)となる量のヒアルロン酸ナトリウム、該点眼液中の濃度が0.001~0.002%(w/v)となる量のベンザルコニウム塩化物、該点眼液中の濃度が0.1~1.0%(w/v)となる量のプロピレングリコール、および該点眼液の浸透圧比が0.9~1.1となる量のイオン性等張化剤を混合するステップ(a);
該点眼液のpHを6.0~7.0に調整するステップ(b);および
該点眼液を点眼容器に充填するステップ(c)を含む、方法。 - ステップ(a)において、さらに該点眼液中の濃度が0.001~0.1%(w/v)となる量のエデト酸塩を混合する、請求項9または10に記載の方法。
- ステップ(a)において、該点眼液中の濃度が0.25~0.75%(w/v)となる量のプロピレングリコールを混合する、請求項9または10に記載の方法。
- ステップ(a)において、該点眼液中の濃度が0.001~0.0015%(w/v)となる量のベンザルコニウム塩化物を混合する、請求項9または10に記載の方法。
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/116,459 US20140088039A1 (en) | 2011-06-23 | 2012-06-22 | Ophthalmic solution containing hyaluronic acid or salt thereof and propylene glycol |
MX2013015273A MX345216B (es) | 2011-06-23 | 2012-06-22 | Solucion oftalmica que contiene acido hialuronico o sal del mismo y propilenglicol. |
EP12802671.3A EP2684560A4 (en) | 2011-06-23 | 2012-06-22 | OPHTHALMIC SOLUTION WITH HYALURONIC ACID OR A SALT AND PROPYLENE GLYCOL |
CN201280029945.5A CN103608000B (zh) | 2011-06-23 | 2012-06-22 | 含有透明质酸或其盐以及丙二醇的滴眼液 |
NZ618822A NZ618822B2 (en) | 2011-06-23 | 2012-06-22 | Ophthalmic solution containing hyaluronic acid or salt thereof and propylene glycol |
KR1020137034299A KR101906631B1 (ko) | 2011-06-23 | 2012-06-22 | 히알루론산 또는 그의 염 및 프로필렌글리콜을 함유하는 점안액 |
BR112013033060A BR112013033060A2 (pt) | 2011-06-23 | 2012-06-22 | solução oftálmica contendo ácido hialurônico ou sal deste e propileno glicol |
CA2839822A CA2839822A1 (en) | 2011-06-23 | 2012-06-22 | Ophthalmic solution containing hyaluronic acid or salt thereof and propylene glycol |
AU2012274367A AU2012274367A1 (en) | 2011-06-23 | 2012-06-22 | Ophthalmic solution containing hyaluronic acid or salt thereof and propylene glycol |
EA201490127A EA025078B1 (ru) | 2011-06-23 | 2012-06-22 | Офтальмологический раствор, содержащий гиалуроновую кислоту или ее соль и пропиленгликоль |
HK14103291.4A HK1190089A1 (zh) | 2011-06-23 | 2014-04-04 | 含有透明質酸或其鹽以及丙二醇的滴眼液 |
AU2017203905A AU2017203905B2 (en) | 2011-06-23 | 2017-06-09 | Ophthalmic solution containing hyaluronic acid or salt thereof and propylene glycol |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011-139566 | 2011-06-23 | ||
JP2011139566 | 2011-06-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012176865A1 true WO2012176865A1 (ja) | 2012-12-27 |
Family
ID=47422693
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2012/065957 WO2012176865A1 (ja) | 2011-06-23 | 2012-06-22 | ヒアルロン酸またはその塩およびプロピレングリコールを含有する点眼液 |
Country Status (16)
Country | Link |
---|---|
US (1) | US20140088039A1 (ja) |
EP (1) | EP2684560A4 (ja) |
JP (1) | JP5981783B2 (ja) |
KR (1) | KR101906631B1 (ja) |
CN (1) | CN103608000B (ja) |
AU (2) | AU2012274367A1 (ja) |
BR (1) | BR112013033060A2 (ja) |
CA (1) | CA2839822A1 (ja) |
EA (1) | EA025078B1 (ja) |
GE (1) | GEP20166459B (ja) |
HK (1) | HK1190089A1 (ja) |
MX (1) | MX345216B (ja) |
MY (1) | MY176112A (ja) |
SG (1) | SG10201605080VA (ja) |
TW (2) | TW201309306A (ja) |
WO (1) | WO2012176865A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016143708A1 (ja) * | 2015-03-06 | 2016-09-15 | 参天製薬株式会社 | 眼科用組成物 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017110874A1 (ja) * | 2015-12-22 | 2017-06-29 | 日油株式会社 | 涙液油層安定化剤およびこれを含有する点眼剤 |
FR3063649B1 (fr) * | 2017-03-07 | 2021-05-21 | Laboratoire De Rhumatologie Appliquee | Nouvelle solution visco-elastique et son utilisation en rhumatologie |
KR102268002B1 (ko) | 2018-12-26 | 2021-06-23 | (주)휴온스 | 효과 지속성 점안제 조성물 |
KR20230126522A (ko) * | 2022-02-23 | 2023-08-30 | 주식회사 스카이테라퓨틱스 | 고분자 히알루론산의 구조체, 이의 제조방법 및 이를 포함하는 점안 조성물 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01115902A (ja) | 1987-10-30 | 1989-05-09 | Showa Sangyo Co Ltd | ヒアルロン酸の製造法 |
JP2002193815A (ja) * | 2000-12-25 | 2002-07-10 | Ophtecs Corp | 眼手術用角膜乾燥防止点眼剤 |
JP2003002837A (ja) * | 2001-06-21 | 2003-01-08 | Lion Corp | 水性外用剤組成物及び液体組成物の白濁防止方法 |
JP2004359629A (ja) | 2003-06-06 | 2004-12-24 | Rohto Pharmaceut Co Ltd | 粘膜適用液状組成物 |
JP2009161454A (ja) | 2007-12-28 | 2009-07-23 | Lion Corp | 眼科用組成物 |
JP2009196903A (ja) | 2008-02-19 | 2009-09-03 | Lion Corp | 眼科用組成物 |
JP2010229159A (ja) * | 2010-07-09 | 2010-10-14 | Rohto Pharmaceut Co Ltd | 粘膜適用液状組成物 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5322667A (en) * | 1987-03-31 | 1994-06-21 | Sherman Pharmaceuticals, Inc. | Preservative system for ophthalmic and contact lens solutions and method for cleaning disinfecting and storing contact lenses |
JP2530491B2 (ja) * | 1988-12-20 | 1996-09-04 | 参天製薬株式会社 | ヒアルロン酸点眼液 |
JPH1072376A (ja) * | 1996-09-02 | 1998-03-17 | Ofutekusu:Kk | ヒアルロン酸含有点眼水溶液 |
CN1413114A (zh) * | 1999-12-27 | 2003-04-23 | 参天制药株式会社 | 用于稳定泪液层的体系 |
AU2720602A (en) * | 2000-11-08 | 2002-05-21 | Bio Concept Lab | Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers |
KR20070104884A (ko) * | 2004-11-24 | 2007-10-29 | 메드포인트 헬쓰케어 인크. | 아젤라스틴을 포함하는 조성물 및 이의 사용 방법 |
CN1939534B (zh) * | 2005-09-27 | 2010-12-01 | 长春金赛药业股份有限公司 | 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂 |
WO2007074904A1 (ja) * | 2005-12-28 | 2007-07-05 | Wakamoto Pharmaceutical Co., Ltd. | 水性医薬組成物 |
EP2070518A2 (en) * | 2006-07-25 | 2009-06-17 | Osmotica Corp. | Ophthalmic solutions |
BRPI0719514A2 (pt) * | 2006-10-12 | 2014-10-07 | Kyorin Seiyaku Kk | Preparações líquidas aquosas compreendendo gatifloxacina |
EP2308468A1 (en) * | 2009-10-08 | 2011-04-13 | Novaliq GmbH | Novel pharmaceutical composition comprising a macrolide immunosuppressant drug |
-
2012
- 2012-06-22 AU AU2012274367A patent/AU2012274367A1/en not_active Abandoned
- 2012-06-22 US US14/116,459 patent/US20140088039A1/en not_active Abandoned
- 2012-06-22 MY MYPI2013004514A patent/MY176112A/en unknown
- 2012-06-22 EP EP12802671.3A patent/EP2684560A4/en not_active Withdrawn
- 2012-06-22 CA CA2839822A patent/CA2839822A1/en not_active Abandoned
- 2012-06-22 EA EA201490127A patent/EA025078B1/ru not_active IP Right Cessation
- 2012-06-22 JP JP2012140951A patent/JP5981783B2/ja active Active
- 2012-06-22 SG SG10201605080VA patent/SG10201605080VA/en unknown
- 2012-06-22 TW TW101122328A patent/TW201309306A/zh unknown
- 2012-06-22 KR KR1020137034299A patent/KR101906631B1/ko active IP Right Grant
- 2012-06-22 MX MX2013015273A patent/MX345216B/es active IP Right Grant
- 2012-06-22 WO PCT/JP2012/065957 patent/WO2012176865A1/ja active Application Filing
- 2012-06-22 GE GEAP201213357A patent/GEP20166459B/en unknown
- 2012-06-22 BR BR112013033060A patent/BR112013033060A2/pt not_active IP Right Cessation
- 2012-06-22 TW TW106116311A patent/TWI704931B/zh not_active IP Right Cessation
- 2012-06-22 CN CN201280029945.5A patent/CN103608000B/zh not_active Expired - Fee Related
-
2014
- 2014-04-04 HK HK14103291.4A patent/HK1190089A1/zh not_active IP Right Cessation
-
2017
- 2017-06-09 AU AU2017203905A patent/AU2017203905B2/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01115902A (ja) | 1987-10-30 | 1989-05-09 | Showa Sangyo Co Ltd | ヒアルロン酸の製造法 |
JP2002193815A (ja) * | 2000-12-25 | 2002-07-10 | Ophtecs Corp | 眼手術用角膜乾燥防止点眼剤 |
JP2003002837A (ja) * | 2001-06-21 | 2003-01-08 | Lion Corp | 水性外用剤組成物及び液体組成物の白濁防止方法 |
JP2004359629A (ja) | 2003-06-06 | 2004-12-24 | Rohto Pharmaceut Co Ltd | 粘膜適用液状組成物 |
JP2009161454A (ja) | 2007-12-28 | 2009-07-23 | Lion Corp | 眼科用組成物 |
JP2009196903A (ja) | 2008-02-19 | 2009-09-03 | Lion Corp | 眼科用組成物 |
JP2010229159A (ja) * | 2010-07-09 | 2010-10-14 | Rohto Pharmaceut Co Ltd | 粘膜適用液状組成物 |
Non-Patent Citations (4)
Title |
---|
"Iyakuhin Interview Form Kakuketsumaku Johi Shogai Chiryoyo Tenganzai Hyaluronic Acid Na Tengan'eki 0.1% 'Nisshin'", HYALURONIC ACID NA MINI TENGAN'EKI 0.3% 'NISSHIN', November 2010 (2010-11-01), XP008171379 * |
"Japanese Pharmacopoeia" |
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, vol. 32, 2004, pages 180 - 184 |
JAPANESE PHARMACOPOEIA |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016143708A1 (ja) * | 2015-03-06 | 2016-09-15 | 参天製薬株式会社 | 眼科用組成物 |
JP2016166195A (ja) * | 2015-03-06 | 2016-09-15 | 参天製薬株式会社 | 眼科用組成物 |
JP2020138979A (ja) * | 2015-03-06 | 2020-09-03 | 参天製薬株式会社 | 眼科用組成物 |
Also Published As
Publication number | Publication date |
---|---|
AU2017203905B2 (en) | 2019-07-11 |
TW201742620A (zh) | 2017-12-16 |
NZ618822A (en) | 2015-07-31 |
JP5981783B2 (ja) | 2016-08-31 |
SG10201605080VA (en) | 2016-08-30 |
MY176112A (en) | 2020-07-24 |
AU2012274367A1 (en) | 2014-01-23 |
EA201490127A1 (ru) | 2014-04-30 |
MX2013015273A (es) | 2014-04-14 |
HK1190089A1 (zh) | 2014-06-27 |
TW201309306A (zh) | 2013-03-01 |
US20140088039A1 (en) | 2014-03-27 |
AU2017203905A1 (en) | 2017-06-29 |
BR112013033060A2 (pt) | 2017-01-24 |
CN103608000A (zh) | 2014-02-26 |
EA025078B1 (ru) | 2016-11-30 |
EP2684560A4 (en) | 2014-08-06 |
CA2839822A1 (en) | 2012-12-27 |
GEP20166459B (en) | 2016-04-11 |
JP2013028599A (ja) | 2013-02-07 |
MX345216B (es) | 2017-01-18 |
CN103608000B (zh) | 2016-05-11 |
EP2684560A1 (en) | 2014-01-15 |
TWI704931B (zh) | 2020-09-21 |
KR101906631B1 (ko) | 2018-10-10 |
KR20140041586A (ko) | 2014-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10632139B2 (en) | Ophthalmic solution comprising diquafosol | |
KR102607126B1 (ko) | 안과용 조성물 | |
AU2017203905B2 (en) | Ophthalmic solution containing hyaluronic acid or salt thereof and propylene glycol | |
TWI709405B (zh) | 水性點眼液及其應用 | |
JP6683622B2 (ja) | 眼科用水性組成物 | |
WO2016195073A1 (ja) | 水性点眼液 | |
EP2800573B1 (en) | Ophthalmic composition | |
JP5969872B2 (ja) | フラビンアデニンジヌクレオチドまたはその塩を有効成分として含有する角膜上皮細胞死の抑制剤 | |
KR20120046026A (ko) | 소프트 콘택트 렌즈용 안과 조성물 | |
NZ618822B2 (en) | Ophthalmic solution containing hyaluronic acid or salt thereof and propylene glycol | |
WO2022107791A1 (ja) | ポリヘキサメチレンビグアナイドまたはその塩を含有する水性点眼液 | |
JP5548434B2 (ja) | 皮膚外用薬組成物 | |
JP2022103144A (ja) | ジクアホソルまたはその塩、銀塩およびイオン性等張化剤を含有する水性点眼液 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201280029945.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12802671 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012802671 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14116459 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2839822 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2013/015273 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20137034299 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201490127 Country of ref document: EA Ref document number: A201400626 Country of ref document: UA |
|
ENP | Entry into the national phase |
Ref document number: 2012274367 Country of ref document: AU Date of ref document: 20120622 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13357 Country of ref document: GE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013033060 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112013033060 Country of ref document: BR Kind code of ref document: A2 Effective date: 20131220 |